Keratinocyte skin cancer, including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), is the most common cancer in white-skinned populations, with rapidly increasing incidence over the past 50 years. SCC accounts for about 20% of these cancers and is more prevalent in older adults. Although mortality is low, SCC is a growing burden on healthcare systems due to high morbidity, especially in older populations. This review focuses on SCC in Australia, the United States, and northern Europe, highlighting trends and future challenges. In Australia, SCC incidence is very high, with Queensland showing the highest rates. In the U.S., SCC incidence has increased since 1990, with higher rates in the southeast and western U.S. In Europe, SCC incidence is lower in the north, but rates are rising, particularly in Denmark and Germany. In Germany, SCC incidence has increased significantly, with rates doubling in those over 80 years old. In the Netherlands, SCC incidence has risen sharply since 2002. In Denmark, the rise is attributed to increased use of tanning beds. Mortality rates for keratinocyte skin cancer are low, but SCC has a higher mortality risk than BCC. In the U.S., SCC mortality rates have remained stable, with higher rates in the southern U.S. In the Netherlands, mortality rates have slightly decreased. In Germany, mortality rates have increased in both Saarland and Schleswig-Holstein. SCC patients have a 25% higher risk of all-cause mortality compared to the general population. Nonmelanoma skin cancer is not routinely recorded in cancer registries, leading to underestimation of its burden. In the U.S., data must be obtained from health insurance companies. In Europe, registries have not recorded nonmelanoma skin cancer for a long time. The inclusion of multiple SCCs has increased incidence rates in the Netherlands. Tumor-associated deaths are difficult to determine due to comorbidities, leading to underestimation of mortality. Skin cancer screening in Germany has increased detection rates and incidence. Older adults are more likely to participate in screening. Future trends suggest a continued rise in SCC incidence due to increased UV exposure, climate change, and lifestyle factors. Preventive measures and early detection programs are needed to address the growing burden of SCC. The incidence of SCC is expected to increase by 10-75% over the next 20 years.Keratinocyte skin cancer, including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), is the most common cancer in white-skinned populations, with rapidly increasing incidence over the past 50 years. SCC accounts for about 20% of these cancers and is more prevalent in older adults. Although mortality is low, SCC is a growing burden on healthcare systems due to high morbidity, especially in older populations. This review focuses on SCC in Australia, the United States, and northern Europe, highlighting trends and future challenges. In Australia, SCC incidence is very high, with Queensland showing the highest rates. In the U.S., SCC incidence has increased since 1990, with higher rates in the southeast and western U.S. In Europe, SCC incidence is lower in the north, but rates are rising, particularly in Denmark and Germany. In Germany, SCC incidence has increased significantly, with rates doubling in those over 80 years old. In the Netherlands, SCC incidence has risen sharply since 2002. In Denmark, the rise is attributed to increased use of tanning beds. Mortality rates for keratinocyte skin cancer are low, but SCC has a higher mortality risk than BCC. In the U.S., SCC mortality rates have remained stable, with higher rates in the southern U.S. In the Netherlands, mortality rates have slightly decreased. In Germany, mortality rates have increased in both Saarland and Schleswig-Holstein. SCC patients have a 25% higher risk of all-cause mortality compared to the general population. Nonmelanoma skin cancer is not routinely recorded in cancer registries, leading to underestimation of its burden. In the U.S., data must be obtained from health insurance companies. In Europe, registries have not recorded nonmelanoma skin cancer for a long time. The inclusion of multiple SCCs has increased incidence rates in the Netherlands. Tumor-associated deaths are difficult to determine due to comorbidities, leading to underestimation of mortality. Skin cancer screening in Germany has increased detection rates and incidence. Older adults are more likely to participate in screening. Future trends suggest a continued rise in SCC incidence due to increased UV exposure, climate change, and lifestyle factors. Preventive measures and early detection programs are needed to address the growing burden of SCC. The incidence of SCC is expected to increase by 10-75% over the next 20 years.